High-throughput liquid chromatography–tandem mass spectrometry determination of bupropion and its metabolites in human, mouse and rat plasma using a monolithic column

Abstract

In the present work, a high-throughput LC/MS/MS method using a Chromolith RP-18 ( 50 mm×4.6 mm) monolithic column was developed and partially validated for the determination of bupropion (BUP), an anti-depressant drug, and its metabolites, hydroxybupropion and threo-hydrobupropion (TB), in human, mouse, and rat plasma. A modern integrated liquid chromatograph and an LC/MS/MS system with a TurboIonSpray (TIS) interface were used for the positive electrospray selected reaction monitoring (SRM) LC/MS analyses. Spiked control plasma calibration standards and quality control (QC) samples were extracted by semi-automated 96-well liquid–liquid extraction (LLE) using ethyl acetate. A mobile phase consisting of 8 mM ammonium acetate-acetonitrile (55:45, v/v) delivered isocratically at 5 ml/min, and split post-column to 2 ml/min directed to the TIS, provided the optimum conditions for the chromatographic separation of bupropion and its metabolites within 23 s. The isotope-labeled D 6-bupropion and D 6-hydroxybupropion were used as internal standards. The method was linear over a concentration range of 0.25–200 ng/ml (bupropion and threo-hydrobupropion), and 1.25–1000 ng/ml (hydroxybupropion). The intra- and inter-day assay accuracy and precision were within 15% for all analytes in each of the biological matrices. The monolithic column performance as a function of column backpressure, peak asymmetry, and retention time reproducibility was adequately maintained over 864 extracted plasma injections.